Sofiene Chenini

Sofiene Chenini

Auto-generated profile, based on publicly available information

Sofiene Chenini

Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in SLEEP
Verified
Journal Article
Open access
PDF file
RLRegis Lopez
Regis Lopez
ADAnis Doukkali
Anis Doukkali
LBLucie Barateau
Lucie Barateau
EEElisa Evangelista
Elisa Evangelista
SCSofiene Chenini
Sofiene Chenini
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
To assess the test–retest reliability of the polysomnography–multiple sleep latency test (PSG–MSLT) diagnostic classification and measures and to study the determinants of its variability in patients with narcolepsy type 1 (NT1) or with noncataplectic central disorders of hypersomnolence (NCHS): type 2 (NT2), idiopathic hypersomnia (IH), and unspecified hypersomnolence (unspecified excessive daytime sleepiness [UnsEDS]). PSG–MSLT in drug-free conditions was administered twice (median interval of 1.9 years) in 22 patients with NT1 (10 males, median age 31.2 years) and 75 patients with NCHS (32 males, median age 25.7 years). At the first PSG–MSLT, patients with NCHS were classified as having NT2 (22.7%), IH (26.7%), or UnsEDS (50.6%). A positive PSG–MSLT was confirmed in 72.7% of NT1. The classification consistency at retesting was significantly lower for the NT2 (47.1%), IH (25.0%), and UnsEDS (42.1%) categories than NT1 (81.3%). The between-test mean sleep latency (MSL) variability was significantly different in NT1 and NCHS, with higher changes in NT2 and lower in NT1. A longer test–retest interval was associated with improved MSL and MSLT normalization. Between-test variations in SOREMP number were associated with changes in nocturnal REM sleep parameters and MSL. No association was found with the clinical decision to repeat the evaluation or the disease clinical course. The PSG–MSLT measures and classification are not stable in patients with NCHS, with frequent diagnostic changes, particularly for NT2 and IH, compared with NT1. MSLT needs to be repeated at regular intervals to confirm a stable hypersomnia and provide an accurate diagnosis of NT2 and IH.

9 February 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EEElisa Evangelista
Elisa Evangelista
RLRegis Lopez
Regis Lopez
LBLucie Barateau
Lucie Barateau
SCSofiene Chenini
Sofiene Chenini
ABAdriana Bosco
Adriana Bosco
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers

9 April 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
EEElisa Evangelista
Elisa Evangelista
LBLucie Barateau
Lucie Barateau
RLRegis Lopez
Regis Lopez
SCSofiène Chenini
Sofiène Chenini
IJIsabelle Jaussent
Isabelle Jaussent
Objective To validate the Idiopathic Hypersomnia Severity Scale (IIHSS), a self-report measure of hypersomnolence symptoms, consequences, and responsiveness to treatment. Methods The 14-item IHSS (developed and validated by sleep experts with patients9 feedback) was filled in by 218 participants (2.3% missing data). Among the 210 participants who fully completed the IHSS, there were 57 untreated and 43 treated patients with idiopathic hypersomnia (IH) aged 16 years or older, 37 untreated patients with narcolepsy type 1 (NT1), and 73 controls without sleepiness. IHSS psychometric properties, discriminant diagnostic validity, and score changes with treatment were assessed. Results The IHSS showed good internal consistency and content validity. Factor analysis indicated a 2-component solution with good reliability expressed by satisfactory Cronbach α values. IHSS scores were reproducible without changes in the test–retest evaluation (13 treated and 14 untreated patients). Convergent validity analysis showed that IHSS score was correlated with daytime sleepiness, depressive symptoms, and quality of life in patients with IH. The IHSS score was lower in treated than untreated patients (5–8 unit difference, without ceiling effect). The cutoff value for discriminating between untreated and treated patients was 26/50 (sensitivity 55.8%, specificity 78.9%). IHSS scores were higher in drug-free IH patients than NT1 and controls. The best cutoff value to differentiate between untreated IH patients and controls was 22 (sensitivity 91.1%, specificity 94.5%), and 29 with NT1. Conclusions The IHSS is a reliable and valid clinical tool for the quantification of IH symptoms and consequences that might be useful for patient identification, follow-up, and management.

10 February 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RLRegis Lopez
Regis Lopez
YSYun Shen
Yun Shen
SCSofiene Chenini
Sofiene Chenini
ARAnna Laura Rassu
Anna Laura Rassu
EEElisa Evangelista
Elisa Evangelista
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers

29 January 2020 in SLEEP
Verified
Journal Article
Closed access
PDF file
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
LBLucie Barateau
Lucie Barateau
RLRegis Lopez
Regis Lopez
ARAnna Laura Rassu
Anna Laura Rassu
SCSofiene Chenini
Sofiene Chenini
IJIsabelle Jaussent
Isabelle Jaussent
Study Objectives: To define clinically relevant Narcolepsy Severity Scale (NSS) score ranges, confirm its main performances and sensitivity to medications, and determine whether items need to be weighted. Methods: One hundred and forty-three consecutive untreated and 238 treated adults with narcolepsy type 1 (NT1) completed the NSS, a 15-item self-administered questionnaire (score: 0–57) that assesses the severity and consequences of the five major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS). They also completed the Epworth Sleepiness scale (ESS; daytime sleepiness), Beck Depression Inventory (BDI; depressive symptoms), and EQ5D (quality of life). Results: The mean symptom number (4.3 vs 3.5), NSS total score (33.3 ± 9.4 vs 24.3 ± 10.2), and number of narcolepsy symptoms (five symptoms: 53.1% vs 24.8%; four symptoms: 26.6% vs 22.7%; three symptoms: 15.4% vs 32.4%; two symptoms: 4.9% vs 20.2%) were significantly different between untreated and treated patients (p < 0.0001). DNS was often the third symptom (95.5 per cent). The symptom number was associated with diagnosis delay, age at onset, and ESS and BDI scores. Comparisons with ESS, BDI and EQ5D showed that NSS item weighting was not necessary to highlight between-group differences. Four NSS severity levels were defined (mild, moderate, severe, and very severe) with between-group differences related to treatment. The probability of having ESS ≥ 16, BDI ≥ 20, and EQ-5D < 60 increased with the severity level. Conclusion: NSS is valid, reliable, and responsive to treatment in patients with NT1, with four clinically relevant severity score ranges provided. NSS has adequate clinimetric properties for broadening its use for both clinic and research.

6 February 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
ABAdriana Bosco
Adriana Bosco
RLRegis Lopez
Regis Lopez
LBLucie Barateau
Lucie Barateau
SCSofiene Chenini
Sofiene Chenini
CPCarole Pesenti
Carole Pesenti
Yves DauvilliersYves Dauvilliers
Yves Dauvilliers
Objective To assess the effect of psychostimulant treatments on the 24-hour blood pressure (BP) profile of patients with narcolepsy type 1 (NT1). Methods Heart rate (HR) and BP were monitored for 24 hours and morning endothelial function was evaluated in 160 consecutive patients with NT1: 68 untreated (41 male, median age 34.9 years), 54 treated (32 male, median age 40.9 years), and 38 evaluated twice (21 male, median age 32 years), before and during treatment. Results Patients treated for NT1 showed higher 24-hour, daytime, and nighttime diastolic BP and HR values compared with the untreated group. Similarly, HR as well as 24-hour and daytime systolic BP were increased during treatment in the group evaluated twice. The combination of stimulant and anticataplectic drugs showed a synergistic effect on BP, without differences among stimulant categories. Based on 24-hour BP monitoring, hypertension was diagnosed in 58% of treated patients and in 40.6% of untreated patients. After adjustments for age, sex, and body mass index, the percentage of REM sleep remained associated with 24-hour hypertension in untreated and treated patients. Endothelial function was comparable in treated and untreated patients. Conclusions The finding that patients with NT1 treated with psychostimulants have higher diastolic BP and HR than untreated patients suggests an increased long-term risk of cardiovascular diseases that requires careful follow-up and specific management.